Ideaya Biosciences reported that its uveal melanoma candidate met or exceeded the prespecified success benchmark in a late-stage trial, strengthening its path toward potential regulatory filing in a cancer with limited effective options. Separately, industry commentary highlighted how smarter late-stage trial design choices—such as endpoints, patient selection, and operational execution—can be pivotal to achieving successful readouts, providing context for why meeting clear benchmarks matters. Find out more details in 2 news articles below.